Is CBN legal in Finland?

Formal status

Across the EU, cannabinoid extracts including cannabinol are classified as unauthorised novel foods under Regulation (EU) 2015/2283, and no Union list authorisation exists in any member state.

Finland's food position covers cannabinoids as a class, not cannabidiol alone, so cannabinol has no lawful route as a food or food supplement.

The notable Finnish fact is what cannabinol is not. It is named nowhere in the government decree on substances regarded as narcotics, in any of its annexes and through every amendment to date. It is named nowhere in the decree on psychoactive substances banned from the consumer market, including the consolidation in force from 10 July 2026. And it is not on the Finnish medicines regulator's medicines list, where cannabidiol is. Cannabinol is therefore the one tracked cannabinoid that Finland has not brought within any control instrument.

That is a real asymmetry, but it is not a permission. The medicines list states in its own terms that it is not exhaustive, so a cannabinol product can be classified a medicine case by case without any list entry. Finland has also been amending its psychoactive-substances annex aggressively in this substance family, adding a hydrogenated cannabidiol derivative with effect from 10 July 2026.

Do we sell here?

Yes, for now: Sleep spray, Sleep capsules.

Yes, we ship to Finland.

Cannabinol is not named in any Finnish controlled-substance or banned-substance list, and it is not on the Finnish medicines list either, which sets it apart from cannabidiol. What it does share with every other cannabinoid in Europe is that it has no novel food authorisation, so it cannot be sold as a food supplement anywhere in the EU on that footing.

That is the same position we are in across our European markets, which is why we do not claim a clearance nobody has. See our CBD page for the fuller Finnish picture.

Outlook

The thing to watch here is amendment risk rather than enforcement risk. Finland has been adding semi-synthetic cannabinoids to its controlled and banned lists in sweeping family-wide entries, most recently with effect from July 2026. Cannabinol has stayed outside those sweeps because it is a natural degradation product rather than a semi-synthetic, but the drafting method means a future amendment could capture it without any advance signal.

The practical lesson from elsewhere in Europe is that this kind of change can be invisible in agency summaries and trade coverage, and visible only in the statutory text. We check the amending texts directly rather than the summaries of them.

Translation missing: en.legality.timeline.heading

Liquid error (sections/custom-liquid line 116): The format option 'legality_timeline_date' is not a supported format.

Fimea's decision on the medicines list, 230/2025, enters into force and repeals the 2022 list. Cannabidiol and melatonin are both named in Annex 1; cannabinol is not. The decision states in its own terms that the list is not exhaustive and that not every product containing a listed substance meets the definition of a medicine.

Suomen säädöskokoelma 230/2025